Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.690 -0.010 (-0.59%)
Streaming Delayed Price Updated: 11:47 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share. Raven Industries, Inc. (NASDAQ: RAVN)... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; CNH Industrial To Buy Raven Industries
Following the market opening Monday, the Dow traded up 1.27% to 33,712.27 while the NASDAQ rose 0.32% to 14,075.68. The S&P also rose, gaining 0.87% to 4,202.85. The U.S. has... 
Via Benzinga
Topics Stocks
Aptevo Therapeutics Insights: Return On Capital Employed
In Q1, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported an overall loss of $6.89 million. In Q4,... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Looking Into Aptevo Therapeutics's Return On Capital Employed
During Q1, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $2.42 million. Despite a 1.01% in earnings, the company posted a loss of $6.89 million. In Q4, Aptevo... 
Via Benzinga
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo")... 
From Aptevo Therapeutics
Via AccessWire
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute... 
Via Benzinga
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
- Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving... 
From Aptevo Therapeutics
Via AccessWire
Topics Death Intellectual Property
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.